KRAS and non-small cell lung carcinoma: Although in colorectal cancer K-RAS mutations are the most useful biomarker for selecting patients who are candidate for treatment with anti-EGFR monoclonal antibodies, cetuximab or panitumumab, its role in NSCLC as prognostic or predictive marker is less defined [18].